0 avis
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry
Archive ouverte
Edité par CCSD ; Taylor & Francis -
International audience. In the 12 years since the publication of the first Consensus Paper of the WFSBP on biomarkersof neurodegenerative dementias, enormous advancement has taken place in the field, and theTask Force takes now the opportunity to extend and update the original paper. New conceptsof Alzheimer’s disease (AD) and the conceptual interactions between AD and dementia due toAD were developed, resulting in two sets for diagnostic/research criteria. Procedures for pre-ana-lytical sample handling, biobanking, analyses and post-analytical interpretation of the resultswere intensively studied and optimised. A global quality control project was introduced to evalu-ate and monitor the inter-centre variability in measurements with the goal of harmonisation ofresults. Contexts of use and how to approach candidate biomarkers in biological specimensother than cerebrospinal fluid (CSF), e.g. blood, were precisely defined. Important developmentwas achieved in neuroimaging techniques, including studies comparing amyloid-bpositron emis-sion tomography results to fluid-based modalities. Similarly, development in research laboratorytechnologies, such as ultra-sensitive methods, raises our hopes to further improve analytical anddiagnostic accuracy of classic and novel candidate biomarkers. Synergistically, advancement inclinical trials of anti-dementia therapies energises and motivates the efforts to find and optimisethe most reliable early diagnostic modalities. Finally, the first studies were published addressingthe potential of cost-effectiveness of the biomarkers-based diagnosis of neurodegenerativedisorders.
Consulter en ligne
Suggestions
Du même auteur
